In a notable advancement for hemophilia treatment, Pfizer Inc. (NYSE: PFE) has received U.S. Food and Drug Administration approval for BEQVEZ™ (fidanacogene elaparvovec-dzkt), a one-time gene therapy aimed at adults suffering from moderate to severe hemophilia B. This innovative treatment could significantly alter the treatment landscape for patients traditionally reliant on regular factor IX (FIX) prophylaxis.
A Potential Game-Changer in Hemophilia Care
BEQVEZ is tailored for individuals who are on routine FIX prophylaxis, have a history of life-threatening bleeding, or experience recurrent serious spontaneous bleeding episodes, and have no neutralizing antibodies to the AAVRh74var capsid, as detected by an FDA-approved test.
According to Dr. Adam Cuker, Director of the Penn Comprehensive and Hemophilia Thrombosis Program, BEQVEZ represents a potential paradigm shift, offering patients the possibility to significantly reduce their long-term medical and treatment burdens.
Efficacy Demonstrated in Clinical Trials
The FDA endorsement follows compelling evidence from the pivotal BENEGENE-2 study. This Phase 3 trial revealed that BEQVEZ could lower the annualized rate of bleeding significantly in comparison to traditional prophylaxis, with some patients experiencing zero bleeds over three years of follow-up.
Global Implications and Next Steps
Following its approval in Canada and the ongoing review by the European Medicines Agency (EMA), BEQVEZ has the potential to impact over 38,000 individuals worldwide living with hemophilia B. This therapy promises to ease the constant treatment regimen associated with the disease.
https://www.pfizer.com/news/press-release/press-release-detail/us-fda-approves-pfizers-beqveztm-fidanacogene-elaparvovec
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Sangamo Therapeutics Secures Accelerated Approval Pathway for Gene Therapy in Fabry Disease
Sangamo Therapeutics has announced a major advancement in its gene therapy program for Fabry disease, as the U.S. FDA has provided a clear pathway for Accelerated Approval. This decision could potentially speed up approval timelines by three years, with a Biologics...
[2024/10/18] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
GSK sues Moderna over mRNA vaccine patents, seeks ‘reasonable royalty’
GSK on Tuesday unveiled a lawsuit filed against Moderna in Delaware federal court, alleging that its patented inventions provide the “foundation” for Moderna’s mRNA vaccine portfolio. GSK said it’s looking to recover “a reasonable royalty” for Moderna’s tens of...
Gene Therapy Automatically Converts Omega-6 to Omega-3 Fatty Acids in the Body
Shriners Children's Develops New Technology to Prevent Childhood Obesity ST. LOUIS, Oct. 16, 2024 /PRNewswire/ -- According to the Centers for Disease Control, nearly 20% of children and teens are considered obese. Research shows it can have a dramatic impact on a...
Related Services